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Introduction
Prostate cancer (PCa) is initially regarded as an andro-
gen-dependent disease, as therapeutic androgen ablation
induces massive apoptosis of malignant cells and clini-
cally leads to tumor regression. However, after a remis-
sion period of up to several years, mutations occur and
tumors usually progress despite low circulating andro-
gen levels. Currently, no therapeutic options are avail-
able for the treatment of androgen-independent PCa
[24,25] If the prostate carcinoma stem cell have been
targeted before these mutation occur, the progression to
androgen independence might be prevented [18].
Several theories about the origin of putative human
prostate carcinoma stem cells (PHPCSC) have been
proposed and postulated suggesting that they probably
arise from normal stem cells, transit-amplifying cells
[3,26] or de-differentiated luminal cells [9,14].
New antigens as candidates for identifying these
putative carcinoma stem cells are p63, GSTP1 and
AMACR.
The nuclear protein p63, a homologue of the p53
tumor suppressor gene, is expressed in the basal cell
compartment of the prostate gland tissue. p63-defi-
cient mice showed agenesis of the prostate gland and
severe defects in the development of other organs, sug-
gesting that p63 is necessary for stem-cell mainte-
nance [25].
GSTP1, encoding glutathione S-transferase-π, has
been proposed to be a caretaker gene, protecting cells
against genome damage mediated by oxidants and
electrophiles from inflammation or dietary exposures
[15].
It has been reported that the enzyme marker 
α-methylacyl-CoA-racemase (AMACR) has high
specificity of expression in PCa (compared to benign
processes in the prostate). The AMACR gene,
encodes the enzyme α-methylacyl-CoA-racemase,
which is localized in the cell mitochondria and per-
oxysoma, and plays a role in the fatty acid metabo-
lism [10].
The present study examines the expression of p63,
AMACR and GSTP1 in proliferative inflammatory
atrophy (PIA), which is regarded as a precancerous
state in order to explore the basal cell population for
putative prostate carcinoma stem cells.
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Materials and methods
Tissue specimens. Tissue samples were acquired after radical
prostatectomy (n=30) from the periphery zone of the prostate of
cases including all: PIA, prostate intraepithelial neoplasia (PIN)
and PCa. The average age of the patients was 65 years (from 49 to
80 years old). The paraffin embedded tissue sections were
processed and provided by the Pathology Department of the
University Hospital, Pleven, Bulgaria and evaluated using conven-
tional immunohistochemistry. Routine microscopy with hema-
toxylin-eosin staining was performed prior to the immunohisto-
chemical investigation. The study was approved by the Ethics
Committee of the hospital. Informed consent was asked and
achieved from the patients in accordance with the Helsinki Decla-
ration.
Antibodies. Polyclonal rabbit antibody against GSTP1, and mouse
monoclonal antibody against p63 (clone 4A4) were obtained from
LAB VISION (USA). Monoclonal rabbit anti-AMACR antibody,
clone 13H4 was produced by DAKO (Dakocytomation, USA).
Immunohistochemistry. The tissue sections were tested using
immunohistochemistry with antibodies against AMACR, p63,
GSTP1 on serial tissue section and visualized by peroxidase-based
DAKO LSAB 2 kit (Dako, CA, USA).
Briefly, the paraffin sections were heated up to 57°C in ther-
mostat and immersed in xylene three times for 10 min each and
then hydrated through series of graded alcohols and then in PBS,
pH=7.2. The sections treated that way were incubated with the cor-
responding antibodies for 2 hours at 30°C. After washing with
PBS, the specific binding was detected by DAKO LSAB-2
SYSTEM, based on biotin-streptavidin-peroxidase, and visualized
in pink color, using DAKO AEC substrate chromogen system
(DAKO, CA, USA). Then, the sections were counterstained with
hematoxylin (Sigma, USA) and all were embedded in aqueous
mounting media (70% glycerol aqueous solution). Serial sections
from the same samples but with no first antibody were used as neg-
ative controls and were incubated only with PBS and the DAKO
LSAB-2 SYSTEM.
Quantitative immunohistochemistry (QIHC). Only parts incor-
porating PIA were analyzed for the expression of the investigated
antigens by the basal cell layer cells as well as by the secretory
ones above them. For each case up to 10 PIA lesions were analyzed
with 5 distinct microscopic fields per each. Microphotographs
were acquired at ×100 and ×200 as TIFF image files, using an
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Fig. 1. Expression pattern of investigated antigens in serial slices in PIA; 
a. p63 staining of basal layer (arrows) (magnification ×200); b. p63 posi-
tive basal cells, which p63 expression was quantitatively measured (arrows)
(magnification ×200); c. selected p63-positive basal cells (arrows), and
secretory cells (broken arrows) which GSTP1 expression was quantitative-
ly measured (magnification ×200); d. selected p63-positive basal cells
(arrows), and secretory cells (broken arrows) which AMACR expression
was quantitatively measured (magnification ×200); e. negative control
incubated with PBS.
Olympus CAMEDIA C-5050 (Olympus Corp., Japan) attached to
an "Olympus BX-40" (Olympus Corp., Japan) microscope system.
"GIMP 2" (The GNU image manipulation program) was used as
image-processing software. The sub-images from serial tissue sec-
tions resembling identical cells were further extracted and the
expression levels of the antigens were quantitatively determined.
Chromogen abundance was quantified by determining the
cumulative signal strength of the digital image file of a histologi-
cal relevant region of interest [11,12]. We applied our own modifi-
cation [4] concerning the pixel selection algorithms as well as our
in-house software for the image quantification. The amount of
chromogen per pixel was determined by subtracting the mathemat-
ical energy (EM) of the control slide (i.e., not exposed to primary
antibody) from that in the homologous region of the experimental
slide (i.e., exposed to primary antibody). Chromogen quantity
(EM) is expressed as energy units per pixel (eu/pix). 
Statistical analysis. All data reported herein are valueless and are
reported as energy units per pixel (eu/pix). Statistical evaluations
were performed using "StatGraphics for Windows v.5" (Manugis-
tics, USA). In all instances, data are expressed as the mean ±SEM
(standard error of mean).
Results
The localization of the basal layer in the examined PIA
lesions was immunohistochemicaly determined using
p63 basal nuclei staining (Fig. 1a). Then on sub-
images of the serial slices, the p63+ basal cells were
selected and their corresponding p63 (Fig. 1b), GSTP1
(Fig. 1c) and AMACR (Fig. 1d) expressions were
quantitatively assessed (QIHC). The GSTP1 and
AMACR expressions for most of the overlaying secre-
tory cells were evaluated as well (Fig. 1c and 1d).
Since AMACR expression is believed to strongly
correlate with PCa malignancy [5], the level of tumor
differentiation [7], and cancer-related death [19], we
first evaluated its expression levels in the basal cells.
Since there was statistically significant probability
these data to come from normal distribution (Chi-
Square goodness-of-fit = 6.70, p=0.82; Shapiro-Wilks
W=0.96, p=0.45; both p>0.10) the cell population was
subdivided according AMACR mean value into two
categories: high- and low-expressing AMACR cells
(Fig. 2a). When the p63 expression of the respective
cells belonging to these two groups was compared
using single factor ANOVA, there were statistically
significant difference between their mean values (F-
ratio=31.31, p<0.00001; additionally - Kruskall-Wallis
Test: p=0.0002, Fig. 2b). Then, based on the span
(mean and standard deviation) of these two sub-groups
(high- and low-expressing AMACR), we determined a
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Fig. 2. One-way ANOVA of the mean expression levels of
AMACR (a) in the two subsets of the basal cell population, subdi-
vided by the AMACR mean value into high expressing
(AMACR_H) and low expressing (AMACR_L); One-way
ANOVA of the mean expression levels of corresponding p63 val-
ues (b) of the previously defined subsets (p63_H and p63_L
denote high- and low-AMACR expressing subpopulations accord-
ingly); box-and-whisker with mean and median (notch) of the
expression levels of AMACR, GSTP1 and p63 of two types basal
cells (I and II accordingly) after subdivision by the decided p63
cut-off (c).
value of ~82,0589 eu/pix expression of p63 to be our
cut-off value for subdividing further the basal cells
into subtypes (Fig. 2c).
According to the antigen expression profiles based
on all investigated antigens two types of basal cells,
and one type secretory cells were observed (Table 1).
Type I basal cells had low p63, GSTP1 and high
AMACR expression. Type II basal cells had the same
type of expression as secretory cells. Their p63 and
GSTP1 expression was higher, and the AMACR
expression was lower than type I basal cells. There was
statistically significant difference in the staining inten-
sities of p63, GSTP1 and AMACR among type I and
type II basal cells (p<0.05).
We further performed correlation analysis on the
data for p63 basal cell subtype I and II with their
respective AMACR and GSTP1 values and observed
statistically significant moderately strong correlation
{with R2=47.86%, p<0.01 (p=0.0061) and R2=30.56%,
p<0.01 (p=0.0403) accordingly} between them only in
the case of type I basal cells.
Discussion
The involvement of the different prostate cell types in
prostate carcinogenesis remains unclear. Although
prostate cancers are phenotypically and behaviorally
similar in many respects to secretory cells (i.e., they
express PSA, AR and are androgen dependent),
recent studies suggest that PCa may arise from a
more immature (intermediate) cell type located with-
in the basal or luminal cell layer [2,3]. Evidence sug-
gestive of this hypothesis comes from the identifica-
tion of basal cell associated cytokeratins and genes in
prostate cancer, particularly androgen-independent
tumors [2]. In addition, it is hypothesized that
prostate cancers, like other epithelial and non epithe-
lial cancers, must arise from stem or progenitor cells,
rather than from a terminally differentiated cell type
[3]. However, the identity and localization of such
cell types within the prostate is not known. Based on
many lines of circumstantial evidence the consensus
is that prostatic epithelial stem cells reside in the
basal compartment [20,24].
Signoretti et al. [21] and Parsons et al. [17] have
recently reported that p63 is a basal cell marker
expressed by a majority of prostate epithelial cells in
tissue culture. Although p63 expression is not restrict-
ed to stem cells, the highest expression of p63 occurs
in stem cells and p63 has been suggested to be a mark-
er of epithelial stem/progenitor cells [13,28]. 
In vitro studies have shown that the normal prostate
stem cells lineages possess self-renewal ability and
generate two distinct cell lineages - quiescent neuroen-
docrine cells and actively proliferating p63+/PSCA-
/AR- transit-amplifying cells [8]. The p63+ transit-
amplifying cells lose their p63 expression and shift to
express PSCA, becoming proliferatively quiescent
intermediate cells [8,23]. These ones probably give
rise to terminally differentiated p63- luminal cells [28].
It is believed that somewhere between these two steps
probably arise the putative cancer precursor ("stem")
cells, since many human cancers overexpress p63 [27],
while most PCas and PCa cell lines (DU-145, LNCaP,
and PC-3) have been reported to be p63- [21]. It is also
possible that the putative cancer "stem" cells arise
directly from the prostate stem cells.
Other in vitro studies support at least partially the
idea of the commitment of p63 to the stem cell lineage
differentiation. Tokar et al. have isolated two cell line-
ages resembling normal prostate intermediate and stem
cell populations. They observed that the intermediate
cell lineage have expressed low p63, while stem cell lin-
eage have expressed high p63 and cytokeratin 14 [22]. 
It is believed that PIA lesion is a precursor of
prostate intraepithelial neoplasia (PIN) and PCa [16].
Our results have demonstrated that a part of the basal
cells in PIA, which we designated as type I, have low
p63, GSTP1, and high AMACR expressions. The loss
of GSTP1 function in prostate cells triggers the vul-
nerability of these cells to suffering genomic damages
mediated by both continuous chronic oxidant stress
and dietary heterocyclic amine carcinogens [16]. We
hypothesized that the lack of GSTP1 expression in
type I basal cells suggest for a decreased DNA anti-
damage protection.
AMACR plays a critical role in the peroxisomal β-
oxidation of fatty acid molecules [10]. The first step of
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Table 1. QIHC evaluation of the expression of p63, GSTP1 and AMACR in [eu/pix]. Two types of basal cells and one type secretory cells
were observed. The data represents the mean values of the investigated groups ±SEM (standard error of mean).
the pathway in β-oxidation of branched chain fatty
acids is an oxidation step catalyzed by acyl-CoA oxi-
dases, with the products being oxidized substrate and
hydrogen peroxide [10]. High AMACR expression
suggests that generated hydrogen peroxide throughout
peroxizomal β-oxidation directly influence on type I
basal cells, which most likely have undergone changes
of the genome.
Most of the prostate adenocarcinoma and high
grade prostate intraepithelial neoplasia (HGPIN)
cells do not express p63 suggesting that p63 may pro-
tect prostate epithelial cells against neoplastic trans-
formation, possibly through a tumor suppressor func-
tion [17]. Indeed, the low p63 expression by type I
basal cells, supports the notion that these particular
cells are the direct targets for neoplastic alteration,
since the decrease of p63 expression leads to
increased cell migration and up-regulation of genes
involved in invasion and metastasis and predisposes
to a loss of epithelial and acquisition of mesenchymal
characteristics [1]. p63 is found to be the molecular
switch for initiation of the epithelial stratification
program [6], which further supports the notion of its
necessity for preserving proper epithelial glandular
structure in the prostate. 
The existing correlation between the expression
levels of p63 and AMACR as well as between p63 and
GST only in type I basal cells and the apparent lack of
significant correlation in type II basal cells further
supports this notion. This observation could be
explained by the ability of p63 to influence the expres-
sion of AMACR and GST only in p63-low expression
basal cells, where p63 protective function is dimin-
ished and relatively fewer factors come into place.
Although the origin of prostate carcinoma is still
unknown [18], our investigation suggests that certain
p63+ cells in the basal cell compartment are less pro-
tected and similar to the transit-amplifying actively
proliferating cell lineage (p63+/PSCA-/AR-). Further
complete loss of their p63 resemble the intermediate
cell population as well as cancer cells, where null or
low p63 corresponds to high levels of AMACR.
We propose that these type I basal cells are proba-
bly the first ones that undergo changes and are proba-
bly related to the subsequent tumorogenic alterations,
beginning to lose their GSTP1 and p63, which is relat-
ed with decreased DNA anti-damage protection and
higher possibility of basal cell neoplastic transforma-
tion. Higher levels of AMACR imply a direct hydro-
gen peroxide influence on these cells. 
The similarity of the antigen profile and localiza-
tion of the type I basal cells makes it plausible that
these cells are possibly the putative human prostate
carcinoma stem cells from which PIN and PCa arise.
Further investigations are necessary to isolate this
type of basal cells to confirm their role in the prostate
pathogenesis, which are in progress in our laboratory.
Most importantly, stem cell research will provide
novel therapies in the treatment of prostate cancer. 
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